Search results for "fusion"

showing 10 items of 4513 documents

Molecular basis of a new type of C1q-deficiency associated with a non-functional low molecular weight (LMW) C1q: parallels and differences to other k…

1998

Analysis of an abnormal C1q molecule of individuals of a Moroccan family by ultracentrifugation in sucrose gradients revealed a low molecular weight C1q (LMW-C1q). We investigated the molecular basis of this defect by sequencing all six exons of the three C1q genes. One point mutation in the codon for Gly at position 15 (GGT) of the B chain was found resulting in an amino acid substitution to Asp (GAT). The exchange not only leads to an interruption of the collagen-like motif Gly-X-Y, but also introduces one negatively charged residue per B chain which results in two additional charges per structural subunit (A-B, C-C, A-B). The mutation which has been identified by DNA-sequencing in the C1…

AdultMaleImmunodiffusionAdolescentSequence analysisProtein subunitchemical and pharmacologic phenomenaBiologyComplement Hemolytic Activity AssayPolymerase Chain Reactionlaw.inventionExonlawHumansLupus Erythematosus SystemicPoint MutationChildGenePolymerase chain reactionPharmacologychemistry.chemical_classificationPoint mutationComplement C1qDNAExonsMolecular biologyAmino acidMolecular WeightMoroccoBiochemistrychemistryFemaleUltracentrifugeCollagenSequence AnalysisImmunopharmacology
researchProduct

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-fi…

2017

Myelodysplastic syndromes are characterised by ineffective erythropoiesis. Luspatercept (ACE-536) is a novel fusion protein that blocks transforming growth factor beta (TGF β) superfamily inhibitors of erythropoiesis, giving rise to a promising new investigative therapy. We aimed to assess the safety and efficacy of luspatercept in patients with anaemia due to lower-risk myelodysplastic syndromes.In this phase 2, multicentre, open-label, dose-finding study (PACE-MDS), with long-term extension, eligible patients were aged 18 years or older, had International Prognostic Scoring System-defined low or intermediate 1 risk myelodysplastic syndromes or non-proliferative chronic myelomonocytic leuk…

AdultMaleIneffective erythropoiesismyalgiamedicine.medical_specialtyPediatricsTime FactorsMaximum Tolerated DoseAnemiaActivin Receptors Type IIRecombinant Fusion ProteinsKaplan-Meier EstimateLower riskmedicine.disease_causeRisk AssessmentSeverity of Illness IndexDisease-Free SurvivalDrug Administration Schedule03 medical and health sciences0302 clinical medicineGermanyInternal medicineSeverity of illnessmedicineHumansProspective StudiesProspective cohort studyAdverse effectAgedProportional Hazards ModelsDose-Response Relationship Drugbusiness.industryMyelodysplastic syndromesAnemiaMiddle AgedPrognosismedicine.diseaseSurvival AnalysisActivinsImmunoglobulin Fc FragmentsTreatment OutcomeOncologyMyelodysplastic Syndromes030220 oncology & carcinogenesisFemalemedicine.symptombusiness030215 immunologyThe Lancet Oncology
researchProduct

Ocular Changes in Patients With Mucopolysaccharidosis I Receiving Enzyme Replacement Therapy

2007

Objective To describe the progression of ocular changes in patients with mucopolysaccharidosis I receiving enzyme replacement therapy. Methods Three male and five female patients with mucopolysaccharidosis I were followed up for 4 years while undergoing enzyme replacement therapy with α-L-iduronidase (Aldurazyme). Visual acuity, corneal clouding, intraocular pressure, ophthalmoscopy, and optic disc measurements were performed yearly. Results Vision remained stable in 5 patients and deteriorated by at least 2 Snellen lines in 3 patients. Deterioration in 2 of these patients was related to progressive corneal clouding. Visual acuities improved in 1 patient after bilateral penetrating keratopl…

AdultMaleIntraocular pressuremedicine.medical_specialtyVisual acuityAdolescentgenetic structuresMucopolysaccharidosis Imedicine.medical_treatmentOptic DiskVisual AcuityCorneal DiseasesIduronidaseDouble-Blind MethodOptic Nerve DiseasesMucopolysaccharidosis IHumansMedicineChildInfusions IntravenousPapilledemaIntraocular PressureCorneal transplantationbusiness.industryEnzyme replacement therapyRecombinant Proteinseye diseasesSurgeryOphthalmoscopyOphthalmologymedicine.anatomical_structureDisease ProgressionOptic nerveFemalesense organsmedicine.symptombusinessOptic discArchives of Ophthalmology
researchProduct

MR imaging technique for the diagnosis of pituitary iron overload in patients with transfusion-dependent beta-thalassemia major

1998

To identify the optimal MR imaging technique for diagnosing pituitary iron overload, we compared spin-echo and gradient-echo MR imaging with measurements of pituitary T2 relaxation times in 30 patients with secondary hemochromatosis due to transfusion-dependent beta-thalassemia major and in 10 healthy volunteers. We found that the optimal MR imaging technique to evaluate pituitary iron overload is the gradient-echo T2*-weighted technique, as it best demonstrated signal reduction in the anterior lobe of the pituitary gland.

AdultMaleIron OverloadAdolescentPituitary Glandbeta-ThalassemiaJournal ArticleHumansTransfusion ReactionBlood TransfusionFemaleMagnetic Resonance ImagingHuman
researchProduct

Single region of interest versus multislice T2* MRI approach for the quantification of hepatic iron overload.

2011

Purpose To evaluate the effectiveness of the single ROI approach for the detection of hepatic iron burden in thalassemia major (TM) patients in respect to a whole liver measurement. Materials and Methods Five transverse hepatic slices were acquired by a T2* gradient-echo sequence in 101 TM patients and 20 healthy subjects. The T2* value was calculated in a single region of interest (ROI) defined in the medium-hepatic slice. Moreover, the T2* value was extracted on each of the eight ROIs defined in the functionally independent segments. The mean hepatic T2* value was calculated. Results For patients, the mean T2* values over segments VII and VIII were significantly lower. This pattern was su…

AdultMaleIron OverloadAdolescentSensitivity and SpecificityYoung AdultImaging Three-DimensionalRegion of interestFunctionally independentImage Interpretation Computer-AssistedMedicineCutoffHumansRadiology Nuclear Medicine and imagingMultisliceHepatic ironChildMeasurement variabilitybusiness.industryLiver DiseasesWhole liverHealthy subjectsReproducibility of ResultsTransfusion ReactionMiddle AgedImage EnhancementMagnetic Resonance ImagingFemalebusinessNuclear medicineJournal of magnetic resonance imaging : JMRI
researchProduct

Laparoscopic adrenalectomy: preoperative data, surgical technique and clinical outcomes

2019

Background: laparoscopic adrenalectomy has become the standard treatment for adrenal lesions. The better clinical outcoms of laparoscopic technique are valid for treatment of small benign masses (< 5-6 cm), instead there are still open questions in literature regarding the correct management of larger lesions (> 6 cm) or in case of potentially malignant adrenal tumors. The aim of this study is to evaluate the outcomes of laparoscopic adrenalectomy in a referral surgical department for endocrine surgery. Methods: at the University Hospital Policlinico "P. Giaccone" of Palermo between January 2010 and December 2017 we performed a total of 81 laparoscopic adrenalectomy. We created a retr…

AdultMaleLaparoscopic surgerymedicine.medical_specialtyBlood transfusionmedicine.medical_treatmentOperative TimeAdrenal Gland Neoplasmslcsh:SurgeryLaparoscopic adrenalectomyHemorrhageAdrenal neoplasmAdrenal IncidentalomaLaparoscopic surgeryLesion03 medical and health sciencesPostoperative Complications0302 clinical medicineHumansCushing syndromeMedicinePostoperative PeriodIntraoperative ComplicationsAgedRetrospective StudiesAged 80 and overbusiness.industryResearchPatient SelectionAdrenalectomyStandard treatmentAdrenalectomylcsh:RD1-811General MedicineLength of StayMiddle AgedSurgeryEndocrine surgeryEndocrine surgeryDissection030220 oncology & carcinogenesisFemaleLaparoscopy030211 gastroenterology & hepatologySurgerymedicine.symptombusinessBMC Surgery
researchProduct

Weekly Dose-Dense Cisplatin-Epirubicin-Paclitaxel Administration with Granulocyte Colony-Stimulating Factor Support Does Not Substantially Improve Pr…

2004

Purpose: The present study was aimed at defining the antitumor activity of the cisplatin-epirubicin-paclitaxel (PET) weekly administration with granulocyte colony-stimulating factor (G-CSF) support in chemonaive small-cell lung cancer patients with extensive disease (ED-SCLC). Methods: Chemonaive ED-SCLC patients received cisplatin 30 mg/sqm, epirubicin 50 mg/sqm and paclitaxel 120 mg/sqm, weekly, with G-CSF (5 μg/kg from day 3 to 5) support, for a maximum of 12 weeks. Results: Thirty-nine patients were treated, for a total of 354 cycles delivered. Eight complete (21%), and 22 partial responses (56%) were recorded, giving a 77% (95% Cl = 61-89%) objective response rate (ORR). After 14 (rang…

AdultMaleLung NeoplasmsPaclitaxelMiddle AgedPrognosisSmall-cell lung cancer Weekly chemotherapy Paclitaxel Epirubicin CisplatinSurvival AnalysisDrug Administration ScheduleTreatment OutcomeAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorHumansFemaleCarcinoma Small CellCisplatinInfusions IntravenousAgedEpirubicin
researchProduct

Unique Characteristics of the Intestinal Immune System as an Inductive Site after Antigen Reencounter

2004

Background Immunization prepares the body for a reencounter with the microbe. Information on the targeting of immune effector cells during secondary immune response--that is, lymphocyte homing--is scarce. In the present study, the homing potentials of lymphocytes are examined after antigen reencounter at mucosal versus nonmucosal sites. Methods Orally or parenterally immunized volunteers were reimmunized orally or parenterally with Salmonella typhi Ty21a, and the expression of the gut homing receptor (HR), alpha(4)beta(7), and of the peripheral lymph node HR, L-selectin, was investigated in circulating antigen-specific antibody-secreting cells (ASCs). Lymphocytes were sorted by HR expressio…

AdultMaleLymphocyteReceptors Lymphocyte HomingAdministration OralPriming (immunology)chemical and pharmacologic phenomenaLymphocyte migration into lymph nodeLymphocyte Activation03 medical and health sciences0302 clinical medicineImmune systemAntigenmedicineHumansImmunology and AllergyInfusions ParenteralAntibody-Producing CellsLymphocyte homing receptor030304 developmental biology0303 health sciencesbiologyDrug Administration RoutesTyphoid-Paratyphoid VaccinesSalmonella typhi3. Good healthIntestinesInfectious Diseasesmedicine.anatomical_structureImmune SystemImmunologybiology.proteinFemaleL-selectin030215 immunologyHoming (hematopoietic)The Journal of Infectious Diseases
researchProduct

Usefulness of quantitative peritumoural perfusion and proton spectroscopic magnetic resonance imaging evaluation in differentiating brain gliomas fro…

2016

Objectives The purpose of our study was to evaluate whether peritumoural perfusion weighted and proton spectroscopic magnetic resonance imaging can be used in differentiating between primary gliomas and solitary metastases. Methods Ten low-grade gliomas, eight high-grade gliomas and 10 metastases were prospectively evaluated with magnetic resonance imaging, dynamic susceptibility contrast enhanced perfusion imaging and single-voxel proton magnetic resonance spectroscopy before surgical resection or stereotactic biopsy. Maximal relative cerebral blood volume values were calculated drawing three regions of interest of 2 cm2 in the non-enhancing peritumoural areas. Maximal relative cerebral bl…

AdultMaleMagnetic Resonance SpectroscopyStereotactic biopsyBrain TumorsPerfusion scanningSensitivity and Specificity030218 nuclear medicine & medical imagingDiagnosis DifferentialWhite matter03 medical and health sciences0302 clinical medicineGliomaImage Processing Computer-AssistedmedicineHumansRadiology Nuclear Medicine and imagingmedicine.diagnostic_testBrain Neoplasmsbusiness.industryperfusion weighted magnetic resonance imagingMagnetic resonance spectroscopic imagingMagnetic resonance imagingGliomaGeneral MedicineMiddle AgedPerfusion-Weighted Magnetic Resonance Imagingmedicine.diseaseMagnetic Resonance Imagingmedicine.anatomical_structureBrain gliomaFemaleNeurology (clinical)businessNuclear medicinePerfusion030217 neurology & neurosurgerybrain metastaseThe Neuroradiology Journal
researchProduct

Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability.

1983

With a new formulation, which made intravenous infusion of triamterene (TA) possible, plasma levels and urinary excretion rates of TA and its main metabolite (OH-TA-ester) were measured in a randomized, cross-over trial in 6 healthy volunteers given triamterene 10 mg i.v. and 50 mg p.o. TA and OH-TA-ester were determined by densitometric measurement of native fluorescence after thin layer chromatography. Distribution volumes of the central compartment of TA and OH-TA-ester were 1.49 l/kg and 0.11 l/kg, respectively. Terminal half-lives were 255 min for TA and 188 min for OH-TA-ester after i.v. administration. For TA total plasma clearance was 4.5 l/min and renal plasma clearance 0.22 l/kg. …

AdultMaleMetabolitemedicine.medical_treatmentBiological AvailabilityAbsorption (skin)PharmacologyFirst pass effectchemistry.chemical_compoundPharmacokineticsmedicineHumansPharmacology (medical)Infusions ParenteralPharmacologyTriamtereneChromatographyGeneral MedicineThin-layer chromatographyBioavailabilityKineticschemistryFemaleDiureticmedicine.drugTriamtereneEuropean journal of clinical pharmacology
researchProduct